Relationship Between No/Slow Reflow Phenomenon in Acute Myocardial Infarction Patients After Percutaneous Coronary Intervention and Inflammatory Response
American Journal of Clinical and Experimental Medicine
Volume 7, Issue 4, July 2019, Pages: 93-96
Received: Aug. 26, 2019;
Published: Sep. 27, 2019
Views 619 Downloads 163
Binbin Wang, Emergency Department, Binzhou People's Hospital, Binzhou City, P. R. China
Zhi Xiao, Department of Nephrology, Binzhou People's Hospital, Binzhou City, P. R. China
Nana Peng, Emergency Department, Binzhou People's Hospital, Binzhou City, P. R. China
Background: To explore the relationship between the occurrence of no/slow reflow phenomenon in acute myocardial infarction patients after undergoing percutaneous coronary intervention (PCI) and inflammatory response. Objective: Prospective study was conducted on 519 acute myocardial infarction patients undergoing PCI, in which 509 patients were followed up for one year. Method: The 76 cases with no/slow reflow phenomenon after PCI was the adverse reflow group. One hundred patients were randomly selected from the remaining 443 patients with the Excel random function table as the control group to avoid statistical deviation. Result: The inflammatory indicators, such as the total numbers of white blood cells and neutrophils, high-sensitivity C-reactive protein, mortality, adverse cardiac event. Conclusion: Inflammatory response is related to the occurrence of no/slow reflow phenomenon in acute myocardial infarction patients after PCI, and seriously affects their prognosis.
Relationship Between No/Slow Reflow Phenomenon in Acute Myocardial Infarction Patients After Percutaneous Coronary Intervention and Inflammatory Response, American Journal of Clinical and Experimental Medicine.
Vol. 7, No. 4,
2019, pp. 93-96.
Ambrose JA. Editorial: Managing Coronary Thrombus in the Cath Lab During PCI. Curr Cardiol Rev, 2018, 8: 200-1.
Lazzeri C, Valente S, Chiostri M, Attanà P, Mattesini A, Dini CS, Gensini GF. Comorbidities in stemi patients submitted to primary PCI: Temporal trends and impact on mortality: A 6-year single center experience. Int J Cardiol, 2019, 11 (8): 256-31.
Balghith MA. High Bolus Tirofiban vs Abciximab in Acute STEMI Patients Undergoing Primary PCI - The Tamip Study. Heart Views, 2018, 13 (3): 85-90.
Palmerini T, Genereux P, Caixeta A, Cristea E, Lansky A, Mehran R, Della Riva D, Fahy M, Xu K, Stone GW. A New Score for Risk Stratification of Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The ACUITY-PCI (Acute Catheterization and Urgent Intervention Triage Strategy-Percutaneous Coronary Intervention) Risk Score. JACC Cardiovasc Interv, 2019, 5 (11): 1108-16.
Cohn JN. Fractional flow reserve-guided PCI reduced urgent revascularization at 7 months in coronary artery disease. Ann Intern Med, 157 (10): 5-9.
Huang RL, Thomassee EJ, Park JY, Scott C, Maron DJ, Fredi JL. Clinical Pathway: Helicopter Scene STEMI Protocol to Facilitate Long-Distance Transfer for Primary PCI. Crit Pathw Cardiol, 2019, 11 (4): 193-8.
Jhaveri RR, Reynolds HR, Katz SD, Jeger R, Zinka E, Forman SA, Lamas GA, Hochman JS. Heart Failure in Post-MI Patients With Persistent IRA Occlusion: Prevalence, Risk Factors, and the Long-Term Effect of PCI in the Occluded Artery Trial (OAT). J Card Fail, 2018, 18 (11): 813-21.
Giordano V, Grandjean JG. There is always hope after PCI and stenting. J Cardiovasc Med (Hagerstown), 2019, 13 (11): 766-8.
Knot J, Kala P, Rokyta R, Stasek J, Kuzmanov B, Hlinomaz O, Bĕlohlavek J, Rohac FP, Petr R, Bilkova D, Djambazov S, Grigorov M, Widimsky P. Comparison of outcomes in ST-segment depression and ST-segment elevation myocardial infarction patients treated with emergency PCI: data from a multicentre registry. Cardiovasc J Afr, 2018, 23 (9): 495-500.
Kherada N, Mehran R. Impending savior: Impella 2.5 circulatory support system in high-risk PCI. Catheter Cardiovasc Interv, 2017, 80 (5): 726-7.
Healey JS. Trifecta or Triple Threat? The Challenge of Post-PCI Management in Patients Receiving Chronic Oral Anticoagulant Therapy. Can J Cardiol, 2019, 11 (2): 641-5.
Moscucci M. Public reporting of PCI outcomes and quality of care: one step forward and new questions raised. JAMA, 2018, 308 (14): 1478-9.
Chakrabarti AK, Gibson CM. Optimal selection of STEMI treatment strategies in the current era: benefit of transferring STEMI patients for PCI compared with administration of onsite fibrinolytic therapy. Curr Opin Cardiol, 2019, 27 (6): 651-4.
Berstad MB, Weyergang A, Berg K. Photochemical internalization (PCI) of HER2-targeted toxins: Synergy is dependent on the treatment sequence. Biochim Biophys Acta, 2017, 1820 (12): 1849-58.
Jerónimo Sousa P, Campante Teles R, Brito J, Abecasis J, de Araújo Gonçalves P, Calé R, Leal S, Dourado R, Raposo L, Silva A, Almeida M, Mendes M. Primary PCI in ST-elevation myocardial infarction: Mode of referral and time to PCI. Rev Port Cardiol, 2017, 31 (10): 641-646.
Meier P, Froehlich GM, Yellon DM, Hausenloy DJ. Predicting peri-procedural myocardial infarction during PCI. Heart, 2018, 98 (20): 1471-2.
Srikanth S, Ambrose JA. Pathophysiology of Coronary Thrombus Formation and Adverse Consequences of Thrombus During PCI. Curr Cardiol Rev, 2018, 8 (3): 168-76.